AU2006336612A1 - Azithromycin for treatment of granulomatous rosacea - Google Patents

Azithromycin for treatment of granulomatous rosacea Download PDF

Info

Publication number
AU2006336612A1
AU2006336612A1 AU2006336612A AU2006336612A AU2006336612A1 AU 2006336612 A1 AU2006336612 A1 AU 2006336612A1 AU 2006336612 A AU2006336612 A AU 2006336612A AU 2006336612 A AU2006336612 A AU 2006336612A AU 2006336612 A1 AU2006336612 A1 AU 2006336612A1
Authority
AU
Australia
Prior art keywords
azithromycin
rosacea
treatment
granulomatous
granulomatous rosacea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006336612A
Other languages
English (en)
Inventor
Serena Mraz-Gernhard
Jeffrey Sugarman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Pharmaceutical Sciences Inc
Original Assignee
Dow Pharmaceutical Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences Inc filed Critical Dow Pharmaceutical Sciences Inc
Publication of AU2006336612A1 publication Critical patent/AU2006336612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2006336612A 2005-11-09 2006-11-08 Azithromycin for treatment of granulomatous rosacea Abandoned AU2006336612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73484305P 2005-11-09 2005-11-09
US60/734,843 2005-11-09
PCT/US2006/043339 WO2007086978A2 (en) 2005-11-09 2006-11-08 Azithromycin for treatment of granulomatous rosacea

Publications (1)

Publication Number Publication Date
AU2006336612A1 true AU2006336612A1 (en) 2007-08-02

Family

ID=38309684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006336612A Abandoned AU2006336612A1 (en) 2005-11-09 2006-11-08 Azithromycin for treatment of granulomatous rosacea

Country Status (10)

Country Link
US (1) US20070105788A1 (https=)
EP (1) EP1945227A4 (https=)
JP (1) JP2009514963A (https=)
CN (1) CN101304750A (https=)
AU (1) AU2006336612A1 (https=)
BR (1) BRPI0617693A2 (https=)
CA (1) CA2626551A1 (https=)
RU (1) RU2008122964A (https=)
WO (1) WO2007086978A2 (https=)
ZA (1) ZA200804896B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
US8143227B2 (en) * 2007-09-05 2012-03-27 Dow Pharmaceutical Sciences, Inc. Azithromycin for treatment of skin disorders
MX2010009493A (es) * 2008-02-28 2010-12-20 Rp Scherer Technologies Llc Proceso para minimizar el polimorfismo.
WO2010006306A1 (en) * 2008-07-10 2010-01-14 Inspire Pharmaceuticals, Inc. Method of treating blepharitis
WO2010085572A1 (en) * 2009-01-23 2010-07-29 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with azithromycin
RU2425682C1 (ru) * 2010-04-28 2011-08-10 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ лечения акне средней степени тяжести
US20130274214A1 (en) * 2010-12-29 2013-10-17 Inspire Pharmaceuticals, Inc. Method for treating blepharitis
JP5986632B2 (ja) 2011-06-28 2016-09-06 メディシス ファーマシューティカル コーポレイション 高用量粘膜接着性メトロニダゾール水系ゲル製剤および細菌性膣炎を治療するためのそれらの使用
WO2014100569A1 (en) * 2012-12-20 2014-06-26 Medicis Pharmaceutical Corporation High dosage topical metronidazole gel formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446356C (en) * 2001-05-09 2012-07-10 The Regents Of The University Of Michigan Use of compositions for treating rosacea

Also Published As

Publication number Publication date
JP2009514963A (ja) 2009-04-09
EP1945227A2 (en) 2008-07-23
WO2007086978A2 (en) 2007-08-02
CN101304750A (zh) 2008-11-12
EP1945227A4 (en) 2009-09-30
WO2007086978A3 (en) 2007-11-22
CA2626551A1 (en) 2007-08-02
US20070105788A1 (en) 2007-05-10
ZA200804896B (en) 2009-07-29
RU2008122964A (ru) 2009-12-20
BRPI0617693A2 (pt) 2011-08-02

Similar Documents

Publication Publication Date Title
Del Rosso et al. CUTIS Do Not Copy
das Neves et al. Local treatment of vulvovaginal candidosis: general and practical considerations
Vijayakumar et al. Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review
Schaller et al. State of the art: systemic rosacea management
Del Rosso et al. Long‐term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified‐release capsules once daily
JP2010538066A5 (https=)
Murray et al. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients
EP1570850A1 (en) Topical formulations for treatment of rosacea
US20070105788A1 (en) Azithromycin for treatment of granulomatous rosacea
McKeage et al. Doxycycline 40 mg Capsules (30 mg Immediate-Release/10 mg Delayed-Release Beads) Anti-Inflammatory Dose in Rosacea
Moore Special populations: profiling the effect of obesity on drug disposition and pharmacodynamics
Parodi et al. Treatment of rosacea
EP2086552B1 (en) Azithromycin for the treatment of nodular acne
US20070254025A1 (en) Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
CN103596565A (zh) 塞克硝唑在口腔感染治疗中的应用
WO2017192504A1 (en) Treating activated dermal conditions with agents that target energy metabolism
Gottwald-Hostalek et al. Combination therapy with metformin plus gliclazide in patients with type 2 diabetes
Greydanus Acne vulgaris, acne rosacea, and acne excoriée
Layton Systemic therapy for acne vulgaris
Al-Dhubaibi Treatment of mild to moderate acne with conventional versus two different intermittent doses and continuous low-dose of isotretinoin: a randomized, comparative study
Moncrieff MANAGING ACNE IN THE ERA OF ANTIMICROBIAL STEWARDSHIP.
Hamed et al. The efficacy, safety and tolerance of azithromycin pulse therapy in papulopustular acne in Iraqi patients.
KR20150063040A (ko) 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제
HK1162921A (en) Azithromycin for the treatment of nodular acne

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period